Out of Context: CEO says now not the time to build a 'big
independent biotech'
Context Therapeutics is “cutting all excess fat” so it can stay afloat through 2024, putting nonessential activities on hold to “focus on blocking and tackling for the time being,” CEO Martin Lehr has told Fierce Biotech.
No comments:
Post a Comment